Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Relief Therapeutics Holding's Debt-to-Equity or its related term are showing as below:
XSWX:RLF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.05 Max: 0.26
Current: 0.06
During the past 13 years, the highest Debt-to-Equity Ratio of Relief Therapeutics Holding was 0.26. The lowest was 0.02. And the median was 0.05.
XSWX:RLF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16
vs XSWX:RLF: 0.06
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Relief Therapeutics Holding Debt-to-Equity Related Terms
Relief Therapeutics Holding Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RLF vs KTTA, OSRH, LIMN: Debt-to-Equity Comparison
For the Biotechnology subindustry, Relief Therapeutics Holding's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding (XSWX:RLF) has a Debt-to-Equity of 0.06 as of Jun. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Relief Therapeutics Holding and its competitors. This is 20% above median its historical median of 0.05. Over the past decade, Relief Therapeutics Holding's Debt-to-Equity has ranged from 0.02 to 0.26.
Is Relief Therapeutics Holding's Debt-to-Equity too high?
Relief Therapeutics Holding's current Debt-to-Equity of 0.06 is 20% above median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.26. The Biotechnology industry median Debt-to-Equity is 0.16. Relief Therapeutics Holding's value of 0.06 is 62.5% below this industry median. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Debt-to-Equity compare to KTTA and OSRH?
Relief Therapeutics Holding's Debt-to-Equity of 0.06 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. Relief Therapeutics Holding's value of 0.06 is 62.5% below this benchmark. Historically, Relief Therapeutics Holding's own Debt-to-Equity has ranged from 0.02 to 0.26 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 0.16, Relief Therapeutics Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relief Therapeutics Holding's current Debt-to-Equity of 0.06 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Relief Therapeutics Holding and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relief Therapeutics Holding's current Debt-to-Equity is 0.06, which is 20% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Debt-to-Equity of 0.06. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Debt-to-Equity is 0.06, which is 20% above median its 10-year median of 0.05 and 62.5% below the Biotechnology industry median of 0.16. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Debt-to-Equity is 0.06 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
Debt-to-Equity: 0.06 (20% above median its 10-year median of 0.05)
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
Industry Position: 62.5% below the Biotechnology median
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
